[go: up one dir, main page]

DK3386991T3 - Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase - Google Patents

Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase Download PDF

Info

Publication number
DK3386991T3
DK3386991T3 DK16820106.9T DK16820106T DK3386991T3 DK 3386991 T3 DK3386991 T3 DK 3386991T3 DK 16820106 T DK16820106 T DK 16820106T DK 3386991 T3 DK3386991 T3 DK 3386991T3
Authority
DK
Denmark
Prior art keywords
tyrosinkinase
bruton
inhibitors
polycyclic compounds
polycyclic
Prior art date
Application number
DK16820106.9T
Other languages
English (en)
Inventor
Nidhi Arora
Genesis M Bacani
Joseph Kent Barbay
Scott D Bembenek
Min Cai
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Brahmananda Ghosh
Gang Li
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Yao Wu
Kun Xiao
Feihuang Zhang
Yaoping Zhu
Kevin Kreutter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3386991T3 publication Critical patent/DK3386991T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK16820106.9T 2015-12-10 2016-12-09 Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase DK3386991T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
PCT/US2016/065954 WO2017100662A1 (en) 2015-12-10 2016-12-09 Polycyclic compounds as inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
DK3386991T3 true DK3386991T3 (da) 2020-07-13

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16820106.9T DK3386991T3 (da) 2015-12-10 2016-12-09 Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase

Country Status (30)

Country Link
US (5) US10717745B2 (da)
EP (2) EP3719022A1 (da)
JP (2) JP6835846B2 (da)
KR (1) KR102103395B1 (da)
CN (2) CN108884106A (da)
AR (1) AR107042A1 (da)
AU (1) AU2016366541B2 (da)
BR (1) BR112018011526B1 (da)
CA (1) CA3007990C (da)
CY (1) CY1123263T1 (da)
DK (1) DK3386991T3 (da)
EA (1) EA035168B1 (da)
ES (1) ES2805835T3 (da)
HR (1) HRP20201193T1 (da)
HU (1) HUE049502T2 (da)
IL (1) IL259863B (da)
JO (1) JO3794B1 (da)
LT (1) LT3386991T (da)
MA (2) MA53110A (da)
MD (1) MD3386991T2 (da)
ME (1) ME03803B (da)
MX (1) MX387590B (da)
PL (1) PL3386991T3 (da)
PT (1) PT3386991T (da)
RS (1) RS60604B1 (da)
SI (1) SI3386991T1 (da)
SM (1) SMT202000404T1 (da)
TW (1) TWI729047B (da)
UY (1) UY37015A (da)
WO (1) WO2017100662A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
EP3596087A1 (en) * 2017-03-15 2020-01-22 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
EP3802537A1 (en) 2018-06-11 2021-04-14 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2020208222A1 (en) 2019-04-11 2020-10-15 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as malt1 inhibitors
WO2021139717A1 (zh) * 2020-01-07 2021-07-15 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
WO2022184716A1 (en) 2021-03-03 2022-09-09 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor
JP2024520630A (ja) * 2021-06-04 2024-05-24 ヤンセン ファーマシューティカ エヌ.ベー. ブルトン型チロシンキナーゼの阻害剤及びその使用方法
AU2022305095A1 (en) 2021-06-30 2024-02-15 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
AU2022326183A1 (en) 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
WO2023156599A1 (en) * 2022-02-18 2023-08-24 Janssen Pharmaceutica Nv Synthesis of bruton's tyrosine kinase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
WO2007019191A2 (en) 2005-08-08 2007-02-15 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
PL2529622T3 (pl) 2006-09-22 2018-07-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
WO2010056875A1 (en) * 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
WO2011024869A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
CN112608298A (zh) 2013-03-15 2021-04-06 詹森药业有限公司 用于制备药物的方法和中间体
EP3872075A1 (en) * 2013-12-11 2021-09-01 Biogen MA Inc. Intermediates and processes for the preparation of biaryl compounds
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
JO3794B1 (ar) 2021-01-31
WO2017100662A1 (en) 2017-06-15
MX387590B (es) 2025-03-18
TW201734021A (zh) 2017-10-01
KR20180093974A (ko) 2018-08-22
IL259863A (en) 2018-07-31
US20190276471A1 (en) 2019-09-12
MA53110A (fr) 2021-05-12
RS60604B1 (sr) 2020-08-31
BR112018011526B1 (pt) 2024-02-27
SMT202000404T1 (it) 2020-09-10
US10717745B2 (en) 2020-07-21
NZ742484A (en) 2021-09-24
EP3719022A1 (en) 2020-10-07
CA3007990C (en) 2024-01-02
HUE049502T2 (hu) 2020-09-28
UY37015A (es) 2017-06-30
US12065446B2 (en) 2024-08-20
CY1123263T1 (el) 2021-12-31
JP2018536686A (ja) 2018-12-13
SI3386991T1 (sl) 2020-08-31
MX2018007075A (es) 2018-11-09
US20210101910A1 (en) 2021-04-08
ES2805835T3 (es) 2021-02-15
CN113121562B (zh) 2022-09-13
CN113121562A (zh) 2021-07-16
US11319329B2 (en) 2022-05-03
IL259863B (en) 2020-06-30
US20230097422A1 (en) 2023-03-30
HRP20201193T1 (hr) 2020-11-13
PL3386991T3 (pl) 2021-03-08
PT3386991T (pt) 2020-08-18
EP3386991A1 (en) 2018-10-17
CN108884106A (zh) 2018-11-23
AU2016366541A1 (en) 2018-05-31
US20170283430A1 (en) 2017-10-05
AU2016366541B2 (en) 2021-05-13
AR107042A1 (es) 2018-03-14
EA201891378A1 (ru) 2018-12-28
MD3386991T2 (ro) 2020-11-30
KR102103395B1 (ko) 2020-04-23
JP6835846B2 (ja) 2021-02-24
LT3386991T (lt) 2020-08-25
EP3386991B1 (en) 2020-06-03
BR112018011526A2 (pt) 2018-11-21
EA035168B1 (ru) 2020-05-08
JP2021073286A (ja) 2021-05-13
CA3007990A1 (en) 2017-06-15
ME03803B (me) 2021-04-20
MA43409B1 (fr) 2020-10-28
TWI729047B (zh) 2021-06-01
JP7072690B2 (ja) 2022-05-20
US10934310B2 (en) 2021-03-02
US20240383914A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3302565T3 (da) Faste doseringsformer af palbociclib
RS60982B1 (sr) Jedinjenja korisna kao inhibitori kinaze
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3294720T3 (da) Fremgangsmåde til fremstilling af terpinolenepoxid
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3524255T3 (da) Sammensætning til behandling af acne
DK3350163T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3536324T3 (da) 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3130592T3 (da) ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
DK3021839T3 (da) Sammensætninger for behandling af fibrose
BR112016026046A2 (pt) Uso de compostos de tienotriazolodiazepina